Literature DB >> 10830768

Apoptosis, cellular proliferation and expression of p53 in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause.

X Wu1, A Blanck, M Olovsson, B Möller, R Favini, B Lindblom.   

Abstract

BACKGROUND: Cell proliferation, apoptosis and expression of p53 proteins were studied in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause.
METHODS: Expression of ki-67 and p53 was analyzed by immunohistochemistry and by immunoblotting. Apoptosis was detected by in situ 3' end labelling of cells with DNA fragmentation.
RESULTS: In both the proliferative and the secretory phases, ki-67 expression was higher in leiomyomas than in myometrium and both tissues showed higher expression in the secretory than in the proliferative phase. No difference in apoptotic index was observed between leiomyomas and myometrium or between the proliferative and secretory phases. After menopause, the expression of ki-67 as well as the apoptotic index was lower than in the proliferative and secretory phases and no significant difference between tissues was seen. Both leiomyomas and myometrium showed negative staining for p53. Immunohistochemical results regarding p53 were confirmed by Western blot.
CONCLUSIONS: Our findings indicate that sex steroids influence the growth of leiomyomas by stimulating cell proliferation rather than by affecting apoptosis. The rate of cell proliferation is higher in fertile age than after menopause and appears to be enhanced under the influence of progesterone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10830768

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  7 in total

1.  Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas.

Authors:  J Browning Fitzgerald; Vargheese Chennathukuzhi; Faezeh Koohestani; Romana A Nowak; Lane K Christenson
Journal:  Fertil Steril       Date:  2012-06-22       Impact factor: 7.329

Review 2.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

3.  Expression of p53 and p21(WAF-1), apoptosis, and proliferation of smooth muscle cells in normal myometrium during the menstrual cycle: implication of DNA damage and repair for leiomyoma development.

Authors:  Ayako Suzuki; Masatoshi Kariya; Noriomi Matsumura; Tsukasa Baba; Haruhiko Yagi; Masaki Mandai; Ikuo Konishi; Shingo Fujii
Journal:  Med Mol Morphol       Date:  2012-12-07       Impact factor: 2.309

4.  Presence, actions, and regulation of myostatin in rat uterus and myometrial cells.

Authors:  Pasquapina Ciarmela; Ezra Wiater; Sean M Smith; Wylie Vale
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

5.  GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment.

Authors:  Mikael Engman; Suby Varghese; Kristina Lagerstedt Robinson; Helena Malmgren; Anna Hammarsjö; Birgitta Byström; Parameswaran Grace L Lalitkumar; Kristina Gemzell-Danielsson
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

6.  Application of a Patient Derived Xenograft Model for Predicative Study of Uterine Fibroid Disease.

Authors:  Martin Fritsch; Nicole Schmidt; Ina Gröticke; Anna-Lena Frisk; Christopher S Keator; Markus Koch; Ov D Slayden
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

7.  Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice.

Authors:  Marcelo B Cavalcante; Tatiana D Saccon; Allancer D C Nunes; James L Kirkland; Tamara Tchkonia; Augusto Schneider; Michal M Masternak
Journal:  Aging (Albany NY)       Date:  2020-01-18       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.